Market Opportunity Presbyopia market focus with YUVEZZI dual-agent drop positions Tenpoint to target U.S. and global aging eye demographics, creating sales opportunities through ophthalmology clinics, vision care providers, and patient access channels.

Strategic Partnerships Recent manufacturing partnership with The Ritedose Corporation and DTP program with PHIL indicate a strong emphasis on scalable distribution, home delivery, and affordable access, suggesting sales plays around contract manufacturing relationships and patient access programs.

Growth Initiatives Launch of YUVEZZI in the U.S. and expansion into patient-centric access models open doors for payer engagement, formulary positioning, and direct-to-patient outreach opportunities via partnerships with clinics and specialty ophthalmology networks.

Leadership & Expertise New Chief Medical Officer appointment signals clinical rigor and credibility, enabling opportunities to engage KOLs in presbyopia and ophthalmic innovation for advisory roles, speaking engagements, and joint clinical education campaigns.

R&D & Adjacent Markets Continued pipeline in cell therapy and small-molecule injections for retinal and cataract applications suggests cross-sell potential to ophthalmology centers and research institutions seeking innovative treatment modalities and collaboration in late-stage development.